Fig. 5: Peripheral virus shedding decreases in dual meganuclease-treated mice.
From: Gene editing for latent herpes simplex virus infection reduces viral load and shedding in vivo
a Experimental timeline of ocular infection, meganuclease treatment and viral reactivations with JQ1. b HSV loads in SCGs (b; p = 0.0012, and <0.0001 for CTRL vs AAV/MN no JQ1 and for CTRL vs AAV/MN 2x JQ1, respectively), and TGs (c; p = 0.0089, and 0.0293 for CTRL vs AAV/MN no JQ1 and for CTRL vs AAV/MN 2x JQ1, respectively) of control infected mice either unreactivated (CTRL no JQ1) or reactivated (CTRL 2x JQ1) and infected mice treated with dual therapy delivered with 1.8 × 1012 total AAV dose either unreactivated (AAV/MN no JQ1) or reactivated (AAV/MN 2x JQ1), with n = 12 per group. Percent decrease of HSV loads in treated mice compared to control mice and statistical analysis (unpaired one-tailed Mann-Whitney test with *p < 0.05; **p < 0.01, ****p < 0.0001) are indicated. d, e Virus titers in eye swabs collected daily from day 1 to 4 after two weekly JQ1 reactivations (red arrows) from control infected mice (d) and infected mice treated with dual therapy delivered with 1.8 × 1012 total AAV dose (e). f, g Area under the curve (AUC) analysis after the first (f), and the second (g) JQ1 reactivation from control infected mice either unreactivated (CTRL no JQ1) or reactivated (CTRL 2x JQ1) and infected mice treated with dual therapy delivered with 1.8 × 1012 total AAV dose either unreactivated (AAV/MN no JQ1) or reactivated (AAV/MN 2x JQ1), with n = 12 per group. p values (unpaired one-tailed Mann–Whitney test) are indicated. Each graph shows individual and mean values with standard deviation. AAV loads are shown in Supplemental Fig. 9g–h. Source data are provided as a Source Data file.
